Fibator Tablet contains a combination of Atorvastatin 10mg and Fenofibrate 145mg, formulated to manage dyslipidemia and reduce cardiovascular risk in patients with mixed hyperlipidemia or hypertriglyceridemia. Atorvastatin, a statin, works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis in the liver, thereby lowering low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels while modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor alpha (PPARα), enhancing the breakdown of triglyceride-rich particles and increasing HDL-C levels. The combined action of these agents effectively reduces elevated LDL-C, triglycerides, and increases HDL-C, addressing multiple lipid abnormalities simultaneously. Fibator Tablet is indicated for patients who have not achieved adequate lipid control with monotherapy or lifestyle modifications alone. It is essential to use this medication under medical supervision, as it may cause side effects such as muscle pain, liver enzyme elevation, or gastrointestinal disturbances. Regular monitoring of liver function tests and lipid profiles is recommended during therapy. Patients should inform their healthcare provider of any pre-existing conditions or concomitant medications to avoid potential drug interactions. Fibator Tablet should be taken as prescribed, alongside a cholesterol-lowering diet and lifestyle changes for optimal results.